The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
During the 2021 ASCO Annual Meeting, the AML Hub spoke with Hui Zhang, Guangzhou Women and Children's Medical Center, Guangzhou, CN. We asked, How efficacious is CAR-T in childhood AML?
How efficacious is CAR-T in childhood AML?
Zhang begins by outlining novel approaches to improve prognosis in relapsed/refractory patients, highlighting the increasing role of CAR T-cell therapy in pediatric AML. He then describes the encouraging results and response rates of his project, presented at ASCO. Finally, Zhang discusses which patients might benefit from CAR T-cell therapy, such as those who are unresponsive to tyrosine kinase inhibitors (TKIs).